Type 2 Diabetes Mellitus
📧 Sign up to get email alerts when something new happens for Type 2 Diabetes Mellitus.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS withdrawal · 2015-03-11Clinical Trial Update: Intensive Lifestyle Intervention for Type 2 Diabetics: The KP TLC Pilot [NA]
The KP TLC Pilot trial studying intensive lifestyle intervention for Type 2 Diabetes was withdrawn.
-
CLINICAL_TRIALS withdrawal · 2014-11-17Clinical Trial Update: Surgical Treatment of Type 2 Diabetes in Non-Morbidly Obese Patients [Phase 4]
A Phase 4 trial evaluating a surgical treatment for type 2 diabetes in non-morbidly obese patients has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2014-10-27Clinical Trial Update: Efficacy and Safety of Empagliflozin Versus Sitagliptin in Patients With Type 2 Diabetes [Phase 3]
A Phase 3 trial comparing empagliflozin to sitagliptin in patients with Type 2 diabetes has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2014-10-02Clinical Trial Update: A Cross-Sectional Survey to Evaluate Diabetes Management, Control, Complications, Psychosocial Aspects of Patients With Type 2 Diabetes in Sri Lanka
A cross-sectional survey of Type 2 diabetes mellitus patients in Sri Lanka sponsored by Novo Nordisk A/S has been withdrawn.
-
EMA withdrawal · 2014-09-26EMA Withdrawn: Pioglitazone Krka (pioglitazone hydrochloride) — Krka, d.d., Novo mesto
Pioglitazone Krka (pioglitazone hydrochloride) has been withdrawn from the EU market.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS withdrawal · 2014-06-20Clinical Trial Update: A Study to Assess the Effect of Creon® on Pancreatic Exocrine Insufficiency in Subjects With Diabetes Mellitus Type 2 [Phase 4]
A Phase 4 clinical trial evaluating Creon (pancrelipase) for pancreatic exocrine insufficiency in subjects with type 2 diabetes mellitus has…
-
CLINICAL_TRIALS withdrawal · 2014-06-05Clinical Trial Update: BE Study of the Fixed Dose Combination of 5 mg Saxagliptin and 500 mg Metformin HCl XR Tablet Relative to a 5 mg Saxagliptin (Onglyza™) Tablet and a 500 mg Metformin HCl XR (Glifage® XR Marketed in Brazil by Merck S.A.) Tablet Co-Administered to Healthy Subjects in the Fasted and Fed States [Phase 1]
Phase 1 bioequivalence study comparing a fixed-dose combination tablet of saxagliptin 5 mg and metformin XR 500 mg to co-administered Saxagl…
-
CLINICAL_TRIALS withdrawal · 2014-04-03Clinical Trial Update: Dose-finding Study of LIK066 Compared With Placebo or Sitagliptin to Evaluate Change in HbA1c in Patients With Diabetes [Phase 2]
Phase 2 dose-finding trial of LIK066 in Type 2 diabetes was withdrawn, with the study comparing LIK066 to placebo or sitagliptin to assess H…
-
CLINICAL_TRIALS withdrawal · 2014-03-19Clinical Trial Update: Impact of Web-based Care Management for Poorly Controlled Type 2 Diabetes Mellitus: a Randomized, Controlled Trial [NA]
A randomized controlled trial sponsored by Kaiser Permanente evaluating web-based care management for poorly controlled Type 2 Diabetes Mell…
-
CLINICAL_TRIALS withdrawal · 2014-02-04Clinical Trial Update: Evaluate Adherence to Treatment With Glucophage Sachets Versus Tablets in Diabetes Type 2 Patients Previously Treated With Metformin Tablets [Phase 4]
Phase 4 trial evaluating adherence to Glucophage sachets versus metformin tablets in type 2 diabetes has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2014-01-27Clinical Trial Update: Fasiglifam in Type 2 Diabetic Subjects With Chronic Kidney Disease Stage 4 or 5 on Hemodialysis [Phase 3]
A Phase 3 clinical trial of fasiglifam in type 2 diabetes patients with chronic kidney disease on hemodialysis has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2013-09-06Clinical Trial Update: Effect of Atorvastatin on Vascular Inflammation in Type 2 Diabetes [NA]
A clinical trial studying the effect of atorvastatin on vascular inflammation in type 2 diabetes patients has been withdrawn. The sponsor li…
-
EMA withdrawal · 2013-07-18EMA Withdrawn: Sepioglin (pioglitazone hydrochloride) — Vaia S.A.
Europen EMA withdrawn status for Sepioglin (pioglitazone hydrochloride) by Vaia S.A., originally for type 2 diabetes, with withdrawal decisi…
-
CLINICAL_TRIALS withdrawal · 2013-07-02Clinical Trial Update: A Long-term Trial to Compare the Effects of Liraglutide and Sulphonylurea (Glimepiride) Both in Combination With Metformin on Clinical, Endothelial and Image Markers of Cardiovascular Risk in Patients With Type 2 Diabetes [Phase 4]
A Phase 4 long-term trial comparing liraglutide to glimepiride, both added to metformin, in patients with Type 2 Diabetes has been withdrawn…
-
CLINICAL_TRIALS withdrawal · 2013-03-21Clinical Trial Update: Two Pieces of Fruit to Type 2 Diabetics? [NA]
Clinical trial testing whether consuming two pieces of fruit affects outcomes in Type 2 diabetes mellitus has been terminated.
-
CLINICAL_TRIALS withdrawal · 2013-03-05Clinical Trial Update: Proteus Sustained Behavior Change Study [NA]
Proteus Digital Health-sponsored trial evaluating sustained behavior change for Type 2 diabetes mellitus has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2013-01-15Clinical Trial Update: Customer Support Response Study
A VeraLight-sponsored clinical trial for Type 2 diabetes mellitus has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2012-12-25Clinical Trial Update: A Study to Evaluate ITCA 650 Compared to Sitagliptin for the Treatment of Type 2 Diabetes [Phase 3]
A Phase 3 trial comparing ITCA 650 with sitagliptin for type 2 diabetes has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2012-12-25Clinical Trial Update: A Study to Evaluate ITCA 650 Compared to Glimepiride for the Treatment of Type 2 Diabetes [Phase 3]
A Phase 3 study evaluating ITCA 650 compared to glimepiride for type 2 diabetes has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2012-12-25Clinical Trial Update: A Study to Evaluate ITCA 650 Compared to Glimepiride as Add on Therapy for the Treatment of Type 2 Diabetes [Phase 3]
Phase 3 trial evaluating ITCA 650 as add-on therapy to glimepiride for type 2 diabetes has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2012-08-28Clinical Trial Update: A Multiple-Dose Study of MK-1006 (MK-1006-004)(TERMINATED) [Phase 1]
Phase 1 multiple-dose trial of MK-1006 was terminated, with results posted in 2012.
-
CLINICAL_TRIALS withdrawal · 2012-07-31Clinical Trial Update: A Study on the Effects of Ranolazine on Exercise Duration in Subjects With Chronic Stable Angina and Coronary Artery Disease (CAD) With Type 2 Diabetes Mellitus (T2DM) [Phase 4]
Phase 4 trial evaluating the effects of ranolazine on exercise duration in patients with chronic stable angina and coronary artery disease w…
-
EMA withdrawal · 2012-07-03EMA Application withdrawn: Pioglitazone Teva Generics (pioglitazone hydrochloride) — Teva Pharma B.V.
The EMA withdrew the application for pioglitazone hydrochloride generic by Teva Pharma B.V. (Pioglitazone Teva Generics) for Type 2 diabetes…
-
CLINICAL_TRIALS withdrawal · 2012-06-12Clinical Trial Update: Glycemic Response to Momordica Charantia in Type 2 Diabetes [Phase 2]
Phase 2 study evaluating the glycemic response to Momordica charantia in type 2 diabetes; the trial status is withdrawn.
-
EMA withdrawal · 2012-04-30EMA Application withdrawn: Pioglitazone ratiopharm (pioglitazone) — Ratiopharm GmbH
The EMA withdrawal indicates the pioglitazone application by Ratiopharm GmbH for Type 2 diabetes has been withdrawn.